MENU
  • Brian Nahed blood based biomarker 1

    Drs. Brian Nahed and Shannon Stott are working to develop the first blood based test for patients with brain tumors.

  • Brian Nahed blood based biomarker 2
  • Brian Nahed blood based biomarker 3
  • Brian Nahed blood based biomarker 4

Mission

The MGH Blood Based Biomarker lab is focused on developing the first blood based test for patients with brain tumors.

Advances in neurosurgery, chemotherapy, and radiation therapy have led to exciting breakthroughs in the care of patients however, there remains no real-time test to monitor a patient’s response to therapy and detecting recurrence of disease is limited to MRIs.  Our laboratory strives to offer patients and their physicians a simple blood test which will provide the ability to diagnose and monitor brain tumors in real-time.  Using technology developed at the MGH Cancer Center, Drs. Brian Nahed and Shannon Stott have developed the first device to identify and analyze circulating tumor cells in brain tumor patients and extra-cellular vesicles (exosomes).  Together, Nahed and Stott are developing the only comprehensive blood based test to diagnose, characterize, and monitor patients with brain tumors.

Dr. Brian Nahed is a neurosurgeon specializing in brain tumors with a specific focus on gliomas (low and high grade), glioblastoma, meningiomas and metastatic cancers.

Dr. Shannon Stott is a biomedical engineer specializing in the development of blood based captured devices and the identification and capture of circulating tumor cells and extra-cellular vesicles in cancer.

Intraoperative imaging
Using sophisticated MRI-based diffusion tensor imaging, Dr. Brian Nahed and his colleagues study subcortical fibers tracts to plan a surgical approach, which is stimulated intraoperatively to confirm avoidance of the tracts and to test and preserve function. Dr. Nahed uses multi-modality intraoperative imaging and intraoperative brain mapping including intraoperative ultrasound to detect extent of resection of infiltrative brain tumors, and intraoperative magnetic resonance imaging to accurately detect extent of resection in real-time using the ultrasound.

Read More
Precision surgery
Using sophisticated MRI-based diffusion tensor imaging, Dr. Brian Nahed and his colleagues study subcortical fibers tracts to plan a surgical approach, which is stimulated intraoperatively to confirm avoidance of the tracts and to test and preserve function.

Read More
Research
As a surgeon-scientist, Dr. Brian Nahed’s research aims to develop the first blood-based test to diagnose and monitor brain tumor patients.

Read More

Research

Blood Based Test for Brain Tumors

Drs. Brian Nahed and Shannon Stott, together with a team comprised of biomedical engineers, cancer biologists, and clinicians, are working to develop the first blood based test for patients with brain tumors. Their recent success in capturing circulating tumor cells and exosomes in brain tumor patients serves as the catalyst for their combined effort to develop a comprehensive blood based tests for brain tumors. Nahed and Stott are currently enrolling patients into their translational research study at the MGH.

Publications

Dr. Brian Nahed has authored 104 peer-reviewed publications. A complete list of all his publications can be found on PubMed. He has presented his work at the American Association of Neurological Surgeons, Congress of Neurological Surgeons, Society for Neurooncology, and Council for State Neurosurgical Societies.

For a complete list please visit PubMed.

Recent publications from the Nahed / Stott laboratory

Alvarez-Breckenridge, C, Markson, SC, Stocking, JH, Nayyar, N, Lastrapes, M, Strickland, MR et al.. Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition. Cancer Immunol Res. 2022; :. doi: 10.1158/2326-6066.CIR-21-0870. PubMed PMID:35706413

Gerritsen, JKW, Broekman, MLD, De Vleeschouwer, S, Schucht, P, Jungk, C, Krieg, SM et al.. Global comparison of awake and asleep mapping procedures in glioma surgery: An international multicenter survey. Neurooncol Pract. 2022;9 (2):123-132. doi: 10.1093/nop/npac005. PubMed PMID:35371523 PubMed Central PMC8965050

Gerritsen, JKW, Broekman, MLD, De Vleeschouwer, S, Schucht, P, Jungk, C, Krieg, SM et al.. Decision making and surgical modality selection in glioblastoma patients: an international multicenter survey. J Neurooncol. 2022;156 (3):465-482. doi: 10.1007/s11060-021-03894-5. PubMed PMID:35067847

Mahajan, A, Shih, H, Penas-Prado, M, Ligon, K, Aldape, K, Hu, LS et al.. The Alliance AMBUSH Trial: Rationale and Design. Cancers (Basel). 2022;14 (2):. doi: 10.3390/cancers14020414. PubMed PMID:35053576 PubMed Central PMC8773887

Srinivasan, ES, Grabowski, MM, Nahed, BV, Barnett, GH, Fecci, PE. Laser interstitial thermal therapy for brain metastases. Neurooncol Adv. 2021;3 (Suppl 5):v16-v25. doi: 10.1093/noajnl/vdab128. PubMed PMID:34859229 PubMed Central PMC8633752

Ng, PR, Choi, BD, Aghi, MK, Nahed, BV. Surgical advances in the management of brain metastases. Neurooncol Adv. 2021;3 (Suppl 5):v4-v15. doi: 10.1093/noajnl/vdab130. PubMed PMID:34859228 PubMed Central PMC8633760

Contact

Request an appoint or second opinion

Direct email form: